A Phase 3 interventional study of Zostavax in Prevention of : Herpes-Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 70 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-11.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 5th largest by enrollment, is one of 4 that started in 2007, is one of 9 in phase 3, and was the 7th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →
Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 70 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 9 · Phase 4 8
First in 2001; this study’s year is marked. 4 started in 2007.
This study's enrollment of 759 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 160 across the 29 interventional studies. Of the 28 that completed or were terminated, 20 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
27 studies in Herpes Zoster by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 26 finished, 24 (92%) have results posted.
Among the 27 studies in Herpes Zoster by Merck & Co., Inc, this one is the 7th largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2007, is one of 14 in phase 3, and was the 10th registered.
Merck & Co., Inc’s Herpes Zoster studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 27 in Herpes Zoster:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective:
Immunogenicity To demonstrate that a second dose of ZOSTAVAX® elicits higher varicella-zoster virus (VZV) antibody titres than a first dose of ZOSTAVAX® whether given as a 0-1 month schedule or as a 0-3 month schedule in subjects ≥70 years of age as measured at 4 weeks post-vaccination
Secondary objectives Immunogenicity
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zostavax 0.65mL intramuscular injection administered on Day 0
Biological: Zostavax
Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 1
Biological: Zostavax
Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 3
Biological: Zostavax
Also known as: Zoster vaccine live
Geometric Mean Titer (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks After Each Vaccination: Groups 2 and 3
Blood samples taken at 4 weeks post each vaccination to determine the geometric mean titer (GMT) of VZV antibodies via Glycoprotein Enzyme Linked Immunosorbent Assay (gpELISA).
Time frame: 4 weeks post-dose 1 (Month 1 for all groups) and 4 weeks post-dose 2 (Month 2 for Group 2 and Month 4 for Group 3)
Geometric Mean Titer (GMT) of VZV Antibodies 4 Weeks After Vaccination: Group 1
Blood sample taken at 4 weeks post vaccination to determine the geometric mean titer (GMT) of VZV antibodies via gpELISA.
Time frame: 4 weeks post-dose (Month 1)
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-vaccination to 4 Weeks Post-dose 1 in Groups 1, 2 and 3 and 4 Weeks Post-dose 2 in Groups 2 and 3
Blood sample taken at predose (Day 0) and 4 weeks post each vaccination to determine the geometric mean titer (GMT) of VZV antibodies via gpELISA. The GMFR was calculated following each vaccination as GMT Post-dose/GMT Pre-vaccination
Time frame: Predose and 4 weeks post-dose 1 (Month 1 for all groups) and 4 weeks post-dose 2 (Month 2 for Group 2 and Month 4 for Group 3)
Geometric Mean Titre of VZV Antibodies 12 Months Post-last Dose
Blood sample taken at 1 year post last vaccination to determine the geometric mean titer (GMT) of varicella antibodies via gpELISA.
Time frame: 1 year post final dose for Groups 1, 2, and 3 (Group 1: Month 12; Group 2: 13 Month 13; and Group 3: Month 15)
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-Vaccination To 12 Months Post-dose 1 in Group 1 And From Pre-Vaccination To 12 Months Post-dose 2 in Groups 2 and 3
Blood sample taken at predose and 1 year post last vaccination to determine the GMFR of varicella antibodies via gpELISA. Geometric mean fold rise was calculated for each arm as GMT 12-month post last dose divided by pre-vaccination GMT.
Time frame: predose 1 and 1 year post-last dose (Group 1: Month 12; Group 2: 13 Month 13; and Group 3: Month 15)
Geometric Mean Titre (GMT) of VZV Antibodies 24 and 36 Months Post-dose 1 in Group 1 and the 24 and 36 Months Post-dose 2 in Groups 2 and 3
Blood sample taken at 36 months post last-vaccination to determine the geometric mean titer (GMT) of varicella antibodies via gpELISA.
Time frame: 24 and 36 months post-last dose
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-Vaccination To 24 And 36 Months Post-dose 1 in Group 1 and From Pre-vaccination To 24 And 36 Months Post-dose 2 in Groups 2 and 3
Blood samples were to be taken at predose and 24 months post- last vaccination in Groups 1 , 2, and 3 to determine the GMFR of varicella antibodies via gpELISA. Geometric mean fold rise was to be calculated for each arm as GMT 24-month post last dose divided by pre-vaccination GMT.
Time frame: Predose 1 and 24 and 36 months post-last dose
Percentage of Participants Who Reported a Solicited Injection Site Reaction : Post-dose 1
Participants entered data into daily dairy card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain
Time frame: up to 4 days after 1st vaccination
Percentage of Participants Who Reported a Solicited Injection Site Reaction: Post-dose 2
Participants entered data into daily dairy card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain
Time frame: up to 4 days after 2nd vaccination
Percentage of Participants Who Reported an Unsolicited Injection Site Reaction: Post-dose 1
The percentage of participants who reported an injection site reaction that was not specifically prompted by the diary card within 28 day of 1st vaccination was recorded.
Time frame: up to 28 days after 1st of study drug
Percentage of Participants Who Reported an Unsolicited Injection Site Reaction: Post-dose 2
The percentage of participants that reported an injection site reaction that was not specifically prompted by the diary card within 28 days post-dose 2 was recorded.
Time frame: up to 28 days post-dose 2
Percentage of Participants Who Reported Herpes Zoster or Zoster-like Rash: Post-dose 1
Percentage of participants who reported herpes zoster or zoster-like rash following the 1st dose of vaccine were recorded.
Time frame: up to 28 days post-dose 1
Percentage of Participants Who Reported Herpes Zoster or Zoster-like Rash: Post-Dose 2
Percentage of participants who reported herpes zoster or zoster-like rash following the 2nd dose of vaccine were recorded.
Time frame: up to 28 days post-dose 2
Percentage of Participants Who Reported Varicella or Varicella-like Rash: Post-dose 1
Percentage of participants that reported varicella or varicella-like rash following the 1st dose of vaccine were recorded.
Time frame: up to 28 days post-dose 1
Percentage of Participants Who Reported Varicella or Varicella-like Rash: Post-dose 2
Percentage of participants that reported varicella or varicella-like rash following the 2nd dose of vaccine were recorded.
Time frame: up to 28 days post-dose 2
Percentage of Participants Who Reported a Systemic Adverse Event: Post-dose 1
An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized
Time frame: up to 28 days after 1st vaccination
Percentage of Participants Who Reported a Systemic Adverse Event: Post-dose 2
An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized,
Time frame: up to 28 days after 2nd vaccination
Percentage of Participants Who Reported a Vaccine-related Systemic Adverse Event: Post-dose 1
An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) and were reported as at least possibly related to the vaccine were summarized
Time frame: up to 28 days after 1st vaccination
Percentage of Participants Who Reported a Vaccine-related Systemic Adverse Event: Post-dose 2
An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) and were reported as at least possibly related to the vaccine were summarized,
Time frame: up to 28 days after 2nd vaccination
Percentage of Participants Who Reported a Serious Adverse Event: Post-dose 1
A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE within 28 days of 1st dose of vaccine were recorded.
Time frame: up to 28 days after 1st vaccination
Percentage of Participants Who Reported a Serious Adverse Event: Post-dose 2
A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE within 28 days of 1st dose of vaccine were recorded.
Time frame: up to 28 days after 2nd vaccination
Percentage of Participants Who Reported a Vaccine-related Serious Adverse Event
A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE during the entire study period that was considered at least possibly -related to the vaccine were recorded.
Time frame: up to end of study (approximately 15 months)
Percentage of Participants Who Died During the Study
The number of participants who died for any reason during the study was summarized.
Time frame: up to end of study (approximately 15 months)
A total of 779 participants were screened. Twenty participants were not randomized.
| Milestone | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Started | 253 | 255 | 251 |
| Received at least 1 vaccination | 253 | 254 | 250 |
| Completed | 250 | 229 | 225 |
| Not completed | 3 | 26 | 26 |
| Withdrew: Adverse event | 0 | 4 | 6 |
| Withdrew: Definitive contra-indication | 0 | 2 | 3 |
| Withdrew: Protocol violation | 0 | 1 | 3 |
| Withdrew: Withdrawal by subject | 3 | 16 | 13 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Other | 0 | 2 | 1 |
| Milestone | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Started | 250 | 229 | 225 |
| Completed | 243 | 220 | 215 |
| Not completed | 7 | 9 | 10 |
| Withdrew: Adverse event | 3 | 3 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 4 |
| Withdrew: Withdrawal by subject | 2 | 6 | 5 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Milestone | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Started | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Started | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
Blood samples taken at 4 weeks post each vaccination to determine the geometric mean titer (GMT) of VZV antibodies via Glycoprotein Enzyme Linked Immunosorbent Assay (gpELISA).
| gpELISA units/mL | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|
| Post Dose 1 | 498.8 (438.7 to 567.1) | 523.3 (459.0 to 596.7) |
| Post Dose 2 | 555.3 (496.6 to 620.9) | 410.5 (363.1 to 464.2) |
Blood sample taken at 4 weeks post vaccination to determine the geometric mean titer (GMT) of VZV antibodies via gpELISA.
| gpELISA units/mL | Group 1: Single Dose of Zostavax |
|---|---|
| GMT Pre-Dose | 233.7 (207.1 to 263.7) |
| GMT Post Dose | 550.0 (489.2 to 618.4) |
Blood sample taken at predose (Day 0) and 4 weeks post each vaccination to determine the geometric mean titer (GMT) of VZV antibodies via gpELISA. The GMFR was calculated following each vaccination as GMT Post-dose/GMT Pre-vaccination
| gpELISA units/mL | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| GMFR Post Dose 1 | 2.35 (2.11 to 2.62) | 2.37 (2.11 to 2.66) | 2.29 (2.05 to 2.57) |
| GMFR Post Dose 2 | NA (NA to NA) | 2.64 (2.37 to 2.95) | 1.80 (1.63 to 1.98) |
Blood sample taken at 1 year post last vaccination to determine the geometric mean titer (GMT) of varicella antibodies via gpELISA.
| gpELISA units/mL | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Geometric Mean Titre of VZV Antibodies 12 Months Post-last Dose | 246.8 (230.9 to 263.9) | 261.1 (242.8 to 280.7) | 266.6 (248.6 to 285.8) |
Blood sample taken at predose and 1 year post last vaccination to determine the GMFR of varicella antibodies via gpELISA. Geometric mean fold rise was calculated for each arm as GMT 12-month post last dose divided by pre-vaccination GMT.
| gpELISA units/mL | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Geometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-Vaccination To 12 Months Post-dose 1 in Group 1 And From Pre-Vaccination To 12 Months Post-dose 2 in Groups 2 and 3 | 1.06 (0.99 to 1.14) | 1.16 (1.06 to 1.26) | 1.17 (1.07 to 1.27) |
Blood sample taken at 36 months post last-vaccination to determine the geometric mean titer (GMT) of varicella antibodies via gpELISA.
No measurements were reported for this outcome.
Blood samples were to be taken at predose and 24 months post- last vaccination in Groups 1 , 2, and 3 to determine the GMFR of varicella antibodies via gpELISA. Geometric mean fold rise was to be calculated for each arm as GMT 24-month post last dose divided by pre-vaccination GMT.
No measurements were reported for this outcome.
Participants entered data into daily dairy card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Reported a Solicited Injection Site Reaction : Post-dose 1 | 47.2 | 46.0 | 42.2 |
Participants entered data into daily dairy card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Reported a Solicited Injection Site Reaction: Post-dose 2 | — | 42.2 | 42.1 |
The percentage of participants who reported an injection site reaction that was not specifically prompted by the diary card within 28 day of 1st vaccination was recorded.
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Reported an Unsolicited Injection Site Reaction: Post-dose 1 | 5.6 | 4.8 | 0.8 |
The percentage of participants that reported an injection site reaction that was not specifically prompted by the diary card within 28 days post-dose 2 was recorded.
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Reported an Unsolicited Injection Site Reaction: Post-dose 2 | — | 1.3 | 3.2 |
Percentage of participants who reported herpes zoster or zoster-like rash following the 1st dose of vaccine were recorded.
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Reported Herpes Zoster or Zoster-like Rash: Post-dose 1 | 0.8 | 0.0 | 0.0 |
Percentage of participants who reported herpes zoster or zoster-like rash following the 2nd dose of vaccine were recorded.
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Reported Herpes Zoster or Zoster-like Rash: Post-Dose 2 | — | 0.0 | 0.0 |
Percentage of participants that reported varicella or varicella-like rash following the 1st dose of vaccine were recorded.
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Reported Varicella or Varicella-like Rash: Post-dose 1 | 0.0 | 0.0 | 0.0 |
Percentage of participants that reported varicella or varicella-like rash following the 2nd dose of vaccine were recorded.
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Reported Varicella or Varicella-like Rash: Post-dose 2 | — | 0.4 | 0.5 |
An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Reported a Systemic Adverse Event: Post-dose 1 | 25.8 | 32.7 | 25.7 |
An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized,
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Reported a Systemic Adverse Event: Post-dose 2 | — | 20.7 | 15.4 |
An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) and were reported as at least possibly related to the vaccine were summarized
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Reported a Vaccine-related Systemic Adverse Event: Post-dose 1 | 6.7 | 4.0 | 8.4 |
An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) and were reported as at least possibly related to the vaccine were summarized,
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Reported a Vaccine-related Systemic Adverse Event: Post-dose 2 | — | 3.4 | 2.7 |
A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE within 28 days of 1st dose of vaccine were recorded.
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Reported a Serious Adverse Event: Post-dose 1 | 0.4 | 2.8 | 0.4 |
A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE within 28 days of 1st dose of vaccine were recorded.
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Reported a Serious Adverse Event: Post-dose 2 | — | 0.9 | 0.9 |
A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE during the entire study period that was considered at least possibly -related to the vaccine were recorded.
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Reported a Vaccine-related Serious Adverse Event | 0.0 | 0.0 | 0.0 |
The number of participants who died for any reason during the study was summarized.
| Percentage of Participants | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Percentage of Participants Who Died During the Study | 1.6 | 2.0 | 1.2 |
Collected over up to 1 year post-last dose (Group 1: 12 months total; Group 2: 13 months total; Group 3: 14 months total). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Single Dose of Zostavax | — | 4/253 (1.6%) | 122/253 (48.2%) |
| Group 2: Zostavax - Day 0 and Month 1 | — | 11/255 (4.3%) | 144/255 (56.5%) |
| Group 3: Zostavax - Day 0 and Month 3 | — | 4/251 (1.6%) | 132/251 (52.6%) |
| Event | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/253 | 2/255 | 0/251 |
| Coronary artery diseaseCardiac disorders | 0/253 | 0/255 | 1/251 |
| DiverticulitisInfections and infestations | 0/253 | 0/255 | 1/251 |
| Radius fractureInjury, poisoning and procedural complications | 0/253 | 0/255 | 1/251 |
| Ulna fractureInjury, poisoning and procedural complications | 0/253 | 0/255 | 1/251 |
| Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/253 | 0/255 | 1/251 |
| Angina pectorisCardiac disorders | 1/253 | 0/255 | 0/251 |
| Atrial fibrillationCardiac disorders | 1/253 | 1/255 | 0/251 |
| Cardiac failureCardiac disorders | 1/253 | 0/255 | 0/251 |
| DehydrationMetabolism and nutrition disorders | 1/253 | 1/255 | 0/251 |
| Event | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 |
|---|---|---|---|
| Injection site erythemaGeneral disorders | 107/253 | 125/255 | 122/251 |
| Injection site painGeneral disorders | 57/253 | 75/255 | 74/251 |
| Injection site swellingGeneral disorders | 69/253 | 73/255 | 67/251 |
| HeadacheNervous system disorders | 13/253 | 14/255 | 10/251 |
Baseline age missing for 1 participant in Group 2 and 1 participant in Group 3.
| Age, Continuous(years) | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 | Total |
|---|---|---|---|---|
| Mean | 76.2 ± 5.5 | 76.0 ± 5.4 | 76.1 ± 5.3 | 76.1 ± 5.4 |
| Sex: Female, Male(Participants) | Group 1: Single Dose of Zostavax | Group 2: Zostavax - Day 0 and Month 1 | Group 3: Zostavax - Day 0 and Month 3 | Total |
|---|---|---|---|---|
| Female | 148 | 138 | 135 | 421 |
| Male | 105 | 117 | 116 | 338 |
No study locations are listed for this record.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Oct 2007 to primary completion in Jun 2009, 19 months.
Results were first posted in Dec 2017, 8 years 6 months after primary completion.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 19 months is above that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chickenpox Vaccine